4 Stocks Underperforming Today In The Health Services Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 16,095 as of Wednesday, Nov. 27, 2013, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,757 issues advancing vs. 1,109 declining with 149 unchanged.

The Health Services industry currently sits up 0.4% versus the S&P 500, which is up 0.3%. On the negative front, top decliners within the industry include DaVita HealthCare Partners ( DVA), down 0.8%, and Boston Scientific ( BSX), down 0.4%. Top gainers within the industry include HCA Holdings ( HCA), up 1.2%, Intuitive Surgical ( ISRG), up 0.7%, St Jude Medical ( STJ), up 0.9%, Express Scripts ( ESRX), up 0.8% and Covidien ( COV), up 0.5%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Bio-Reference Labs ( BRLI) is one of the companies pushing the Health Services industry lower today. As of noon trading, Bio-Reference Labs is down $7.69 (-20.4%) to $30.04 on heavy volume. Thus far, 2.5 million shares of Bio-Reference Labs exchanged hands as compared to its average daily volume of 215,400 shares. The stock has ranged in price between $29.35-$34.99 after having opened the day at $34.83 as compared to the previous trading day's close of $37.73.

Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases primarily in the greater New York metropolitan area. Bio-Reference Labs has a market cap of $1.0 billion and is part of the health care sector. The company has a P/E ratio of 21.8, above the S&P 500 P/E ratio of 17.7. Shares are up 31.8% year to date as of the close of trading on Tuesday. Currently there is 1 analyst that rates Bio-Reference Labs a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Bio-Reference Labs as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Bio-Reference Labs Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, ResMed ( RMD) is down $0.80 (-1.6%) to $48.77 on average volume. Thus far, 463,248 shares of ResMed exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $48.65-$49.41 after having opened the day at $49.34 as compared to the previous trading day's close of $49.57.

ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. ResMed has a market cap of $7.2 billion and is part of the health care sector. The company has a P/E ratio of 23.4, above the S&P 500 P/E ratio of 17.7. Shares are up 19.2% year to date as of the close of trading on Tuesday. Currently there are 7 analysts that rate ResMed a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full ResMed Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Laboratory Corporation of America Holdings ( LH) is down $2.59 (-2.5%) to $102.46 on heavy volume. Thus far, 840,416 shares of Laboratory Corporation of America Holdings exchanged hands as compared to its average daily volume of 636,800 shares. The stock has ranged in price between $101.32-$106.17 after having opened the day at $104.90 as compared to the previous trading day's close of $105.05.

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. Laboratory Corporation of America Holdings has a market cap of $9.3 billion and is part of the health care sector. The company has a P/E ratio of 17.4, below the S&P 500 P/E ratio of 17.7. Shares are up 21.3% year to date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Laboratory Corporation of America Holdings a buy, 2 analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Laboratory Corporation of America Holdings as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, growth in earnings per share, revenue growth, notable return on equity and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Laboratory Corporation of America Holdings Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Quest Diagnostics ( DGX) is down $1.09 (-1.8%) to $60.99 on average volume. Thus far, 1.1 million shares of Quest Diagnostics exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $60.71-$62.13 after having opened the day at $61.86 as compared to the previous trading day's close of $62.08.

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. Quest Diagnostics has a market cap of $9.1 billion and is part of the health care sector. The company has a P/E ratio of 12.0, below the S&P 500 P/E ratio of 17.7. Shares are up 7.0% year to date as of the close of trading on Tuesday. Currently there are 4 analysts that rate Quest Diagnostics a buy, 3 analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, increase in net income, notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Quest Diagnostics Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Stocks Trim Losses in Final Minutes of Trading

Stocks Trim Losses in Final Minutes of Trading

Overstock Needs a Catalyst, Says Analyst

Overstock Needs a Catalyst, Says Analyst

American Express Shares Climb After Winning Supreme Court Case

American Express Shares Climb After Winning Supreme Court Case

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Watch: Here's What Wall Street Is Tracking Monday as Trump Sends Stocks Lower

Watch: Here's What Wall Street Is Tracking Monday as Trump Sends Stocks Lower